Sandoz INC.
Reporting payments is a legal requirement; large totals often reflect large product portfolios.
$946Kgeneral payments (2019-2025)
$30Kresearch payments (2019-2025)
8,802clinicians paid
General and research payments are shown separately, never blended. Research payments are often institution-directed and tied to clinical trials.
General payments by year
General payments only, as reported to CMS. Research payments are totaled above and not included in these bars.
Products most associated with its payments
- Hyrimoz $206K associated (2023-2025)
- Cimerli $82K associated (2023-2025)
- Jubbonti $16K associated (2023-2025)
- Treprostinil $15K associated (2023-2025)
- Omnitrope $1,777 associated (2023-2025)
- Enoxaparin Sodium $1,597 associated (2023-2025)
- Wyost $1,012 associated (2023-2025)
- Tyruko $833 associated (2023-2025)
- Cyclophosphamide $501 associated (2023-2025)
- Pyzchiva $469 associated (2023-2025)
- Zarxio $385 associated (2023-2025)
- Ziextenzo $263 associated (2023-2025)
Specialties it works with most
Clinicians with the largest reported totals
Often long-running consulting, speaking, or advisory relationships, which companies must report by law. A large total is not evidence of anything improper.
| Clinician | Location | Specialty | General payments (2019-2025) |
|---|---|---|---|
| Gary Lyman | Seattle, WA | Medical Oncology | $46,986.61 |
| Robert Shin | Charlottesville, VA | Neurology (Psychiatry & Neurology) | $22,236.23 |
| Nicole Kuderer | Seattle, WA | Hematology & Oncology | $20,915.75 |
| Dilsher Dhoot | Santa Barbara, CA | Retina Specialist | $20,833.75 |
| Steven Chernausek | Oklahoma City, OK | Pediatric Endocrinology | $18,858.75 |
| Benjamin Greenberg | Dallas, TX | Neurology (Psychiatry & Neurology) | $18,490.00 |
| Jonathan Kay | Worcester, MA | Rheumatology | $17,644.94 |
| Jeffrey Curtis | Birmingham, AL | Rheumatology | $16,448.25 |
| Kavita Mariwalla | West Islip, NY | Mohs-Micrographic Surgery | $16,000.00 |
| Michael Singer | San Antonio, TX | Ophthalmology | $14,536.28 |
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.